ArticleInternational journal of genomics2026
Downregulation of IFNG-AS1 and UCHL1-AS1 in Peripheral Blood Cells of Multiple Sclerosis Patients: IFNG-AS1 as a Candidate Diagnostic Biomarker.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is a neurodegenerative and inflammatory disease affecting gray and white matter in the brain. Due to the highly variable presentation of MS, making a reliable long-term diagnosis based solely on initial clinical findings is extremely challenging. Long noncoding RNAs (lncRNAs) have been shown in recent research to have a role as prospective biomarkers that may offer data to forecast the onset and course of disease. Methods: A total of 100 healthy controls and 120 MS patients with 98 relapsing-remitting (RR), 10 primary progressive (PP), and 12 secondary progressive (SP) cases were included in the blood sample collection. Gene expression was assessed with quantitative real-time PCR. The receiver operating characteristic (ROC) curve analysis was employed to evaluate the potential for diagnostic analysis of lncRNA levels. Results: The expressions of IFNG-AS1 and UCHL1-AS1 were found to be significantly decreased ( Conclusion: IFNG-AS1 demonstrates promising diagnostic potential for MS, whereas UCHL1-AS1 shows only modest discriminatory value. However, these findings are preliminary and require further validation with functional studies to confirm clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.